The objective of this 12‐week double‐blind randomized multicentre study was to compare
the efficacy and tolerability of nebivolol, a recently developed beta‐blocking agent with …

Objective: The aim of the present study was to evaluate the antihypertensive efficacy of the
highly beta 1-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the …

This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

Nebivolol is a lipophilic β 1-blocker. It is devoid of intrinsic sympathomimetic or membrane
stabilising activity but appears to have nitric oxide-mediated vasodilatory effects. Nebivolol is …

A double-blind, randomised, parallel-group trial was conducted in patients with essential
hypertension in British general practices, of nebivolol 5 mg, atenolol 50 mg, and placebo …

The efficacy and acceptability of nebivolol 5 mg and enalapril 10 mg, each given once daily,
were compared in essential hypertension in a multicentre, randomised, double-blind trial …

The β-adrenergic receptor blockers play an important role in the management of
cardiovascular disease, including hypertension and chronic heart failure. However …

Nebivolol is a novel, β1-adrenergic receptor blocker with vasodilatory properties mediated
through the activation of the l-arginine/nitric oxide pathway. Short-term randomized clinical …

The main objective of this study was to compare the anti-hypertensive efficacy and safety of
nebivolol (5 mg once daily) and lisinopril (20 mg once daily) given for 12 weeks in patients …

Background: The antihypertensive activity of beta-blockers generally increases during the
first 6 to 8 weeks of treatment; however, no study has systematically assessed whether blood …